Analysis of paraffin-embedded mammary carcinoma specimens for the E6 region of the human papillomavirus by Kozma, Corinne Elizabeth
Lehigh University
Lehigh Preserve
Theses and Dissertations
1998
Analysis of paraffin-embedded mammary
carcinoma specimens for the E6 region of the
human papillomavirus
Corinne Elizabeth Kozma
Lehigh University
Follow this and additional works at: http://preserve.lehigh.edu/etd
This Thesis is brought to you for free and open access by Lehigh Preserve. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Kozma, Corinne Elizabeth, "Analysis of paraffin-embedded mammary carcinoma specimens for the E6 region of the human
papillomavirus" (1998). Theses and Dissertations. Paper 534.
· Kozma, Corinne
Elizabeth
Analysis of
Paraffin-
Embedded
Mammary
Carcinoma
····S~pe'eiffl·eA~s";~;>·';·~· ..... ..~".~".==-_.
May 13, 1998
Analysis of Paraffin-Embedded Mammary Carcinoma
Specimens for the E6 Region
of the
Human Papillomavirus
by
Corinne Elizabeth Kozma '
A Thesis
Presented to the Graduate and Research Committee
of Lehigh University
in Candidacy for the Degree of
Master of Science
in the
Department ofBiological Sciences
..,
.. Lehigh University
c--~:.~-'~ ~'~"-"":""'-;::"':.':'.:-~":="~"':=':::"'.'~':':""":':;~~:C'""..-,A:p!H;J29-8.,>= __~;.;~~-.:, ..':,:.~. __ -':"__ '__ '_~--'-'~:-"''''-_~''~;':_:';-;:' __;;'''::''i;.~' __''''''''_'''='"'::_"="+''''''',=

0,'3 t ~ ~ ~;,.tr-'."'--
.....~,'J _.•.--'
Dedication
I dedicate this thesis to my parents. Their support and guidance throughout the
years have allowed me to strive for higher education. In addition, my research was of
personal significance because my mother is a breast cancer survivor.
111
Acknowledgements
I would like to express sincere appreciation to Dr. Jeff Sands for guiding me
through my educational experience at Lehigh University. As one of my committee
members he provided support, encouragement, and suggestions during my study. I
would also like to thank my other committee members, Dr. Vassie Ware and Dr.
Agnes Ayme-Southgate for their advice on my project.
I would like to extend a special thanks to Sheila Mathieson in the Virology _
laboratory for all of her assistance. She spent may extra hours discussing my research
with me and also teaching me necessary procedures and techniques. I also want to
include thanks to Christine Roberts for her helpful advice. Both Sheila and Christine
were a great asset to my work at Lehigh and all of their help is appreciated.
I am especially grateful for all of the support I received from my fiance' Shawn
and my family. I could not have asked for more support and understanding during my
study. Their encouraging words always seemed to arrive at the most difficult times of
my research and allowed me to move ahead to achieve my goals. The support they
have extended to me throughout my study will never be forgotten.
• '7""~:r: ..... ' .......t..:"'~""'-~"-~--'-'-"-;7·.-,~· ....
_.--_ .. -.._,----~_. ------.,_ .. ---- ~-:::~..;- ..._---
IV
Table of Contents
D d' , .. ,e Icatlon , . , , . , . , 111
Aclrn.owledgements , , . , , .. iv
List of Tables.. , , : , , vi
L' fP' ..1st 0 19ures , VII
Abstract , ,., 1
Introduction ~, , 3
Materials and Methods , 13
Results , 23
Discussion ' : , .. , , 31
References , , 50
Vita 55
v
Table 1.
Table 2.
. \
List of Tables
Oligonucleotide HPV E6 Primer Sequences and Locations in the
HPV 16 Genome 35
Detection ofHPV in Mammary Carcinoma Specimens .36
/
\ I
vi
List of Figures
Figure 1. HPV Genome Organization 42
Figure 2. Integration Pattern of the HPV Genome 43
Figure 3. Electrophoresis Results ofMammary Samples 103 - 108 44
Figure 4. Electrophoresis Results of Genital HPV Types and Mammary Samples
120, 19,55,87 and 99 45
Figure 5. Southern Analysis Results of Genital HPV Types and Breast Specimeris
120, 19, 55, 87 and 99 46
Figure 6. Electrophoresis ofHPV SiHa in Serial Dilution and Mammary Samples
30, 35, 59,42 and 79 47
Figure 7. Southern Analysis Results ofSiHa in Dilution and Breast Specimens 30,
35, 59,42 and 79 48
Figure 8. Southern Analysis Results ofMammary Samples 19, 55, 87, 99 and
and 116 49
4 •
VII
.J_•... ,.:.
ABSTRACT
The Papillomaviruses were first recognized as viral particles in 1949 and since
then, it has been determined that HPV, the Human Papillomavirus, is a major
component involved in the pathogenesis of certain cancers, particularly anogenital
carcinomas.50 This finding has led HPVs to emerge as the most well characterized of
the human tumorviruses?7 Recent analysis has now identified HPV as a possible
etiological agent in another frequent lethal malignancy ofwomen.3 It is believed that
HPV may playa role in the development of some cases of breast cancer.3, 12 Research
has demonstrated that HPV types 16 and 18 can immortalize normal human mammary
epithelial cells.3 In order to establish the prevalence of HPVs involvement in breast
carcinomas, an extensive analysis was performed on 129 breast cancer specimens in
our laboratory. Paraffin-embedded breast carcinomas were examined for the presence
or absence of an oncogenic region of the Human Papillomavirus, the HPV E6 region.
DNA was extracted from the specimens and the Polymerase Chain Reaction(pCR) was
performed to determine if HPV DNA was present in the mammary tissue biopsies.
The PCR amplified products were electrophoresed and samples which had a visible
band in the vicinity of 250 basepairs(bp) were considered to be putative HPV positive
samples. These specimens along with others were further analyzed by Southern
hybridization to probes designed to d~tect the most common HPV types found in
genital lesions. Southern analysis showed an HPV E6 band in 12 of the samples,
- ) /
therefore, 9% of these mammary tumors were determined. to have detectable levels of
HPV E6 DNA. Further research will be necessary to determine the molecular
1
mechanisms in which HPV interacts with mammary tissue and also the impact of other
factors in HPV oncogenesis.
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INTRODUCTION
The Human Papillomaviruses (HPVsyare epitheliotropic, double-stranded
DNA viruses which induce epithelial hyperproliferation.8, 19 HPVs have a genome size
of approximately 8 kb and are found to have preference for anatomical sites.8 Thus far,
more than 70 HPV genotypes have been identified.1, 10, 50 Those most' frequently
associated with the genital region include HPV 6, 11, 16, 18,31,33,34, and 35.8,25 In
certain instances, HPV infection has been found to lead to malignant transformation.5,
19 Therefore, these virus types have been classified as "high" or "low" risk.3o The
"high" risk group contains HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 57, 58, 59, and
61.14, 30 If DNA from these "high" risk types is introduced into primary human
keratinocytes it leads to unlimited lifespan in tissue culture. HPV 16 is the most
predominant of the "high" risk category, detected in 60 to 90% of malignant cervical
carcinomas, while HPV 18 has been identified ;15 - 36%.25 HPV 18 is believed to
have the highest oncogenic potential and therefore may progress to malignancy more
rapidly than other "high" risk HPV types.6, 25 HPV DNA has been isolated from about
90% of cervical cancers and overall, HPV related tumors account for approximately
10% of the worldwide cancer statistics.14, 18,50 Cervical carcinomas make up about 6%
of all human cancers.50 The "low" risk HPV types most commonly include HPV 6 and
II(others are HPV 13, 32, 34, 40, 42, 44" 53, 54, 55, and\63).4, 14 The "low" risk
:::;.",o--,-:-:"".~......':,...,.-.,,_, ... - - .:..:...__-....:.:1....~ -.. ,'- -O-. __•• :'::~"'_'. '-"'.'.';":~:~':"-~--.-. ~ ,, .:...__ :.:~_'" '~:::~::'_:~;'_'-""'·:7·'-:'1':"_:'J;~-:;'.-,.:-;-'.:-·,..~·.·;;./~i;.:';F-~:_:",-~~~,t_·,,_ • -.-::;.-,,:\ •.•- '-. ~". ',,' '-':;":':~- -:.-:":'·-'/;;;~;::"5;,-~·~K--:".k('i'!?1J-J-~:~,X;:"Zii ,;.;;,~::.~ ;';-:''''':':~'77.:%o ......
category rarely leads to malignant transformation.14 Instead, "low" risk HPV types are
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vagina or the vulva?7, 32 Many of the "low" risk HPV types have also been identified
in low grade cervical dysplasias and frequently regress spontaneously.I4 Two HPV
proteins, E6 and E7, have been detennined to contribute to the development of.
oncogenesis. 13, 14, SO The E6/E7 genes can cooperatively induce cellular
immortalization, although they do not induce tumorigenesis directly.41 Other non-viral
factors are required in addition to the high-risk HPV infection such as cigarette
smoking, hormones and low serum vitamin levels for the development ofmalignancy.6,
14,20,31 These findings indicate that HPV infection is necessary but not sufficient for
tumorigenesis?' 14,26
Papillomaviruses(PV) are a subfamily of the Papovaviridae family.40,46 The
second subfamily, polyomaviruses, have a different genome than the PV and therefore,
it is believed that these two subfamilies split early in evolution.34 The PV are
nonenveloped and have icosahedral capsids made from 72 capsomers.46 HPV has
been shown to have a similar genomic arrangement for all viral types.27 Their genomes
consist of both early and late genes and, in addition, an upstream regulatory region
(URR) also known as the noncoding region or the long coding region.6,20, 22, 40, 46 The
early genes are expressed at the beginning of viral infection and include information
necessary for viral DNA replication and cell transformation. 1, 6, 40 Late genes are
usually expressed after replication of the genome and encode the virion structure.I, 6, 40
. . ,
---.------~- ... --- Hl?\l'7"genclmes-coiitaili-tlie-Ulte-genes, L1 and-bQ, -which~e""expressed-on1Y'-in~= '''''","-'.'
differentiated keratinocytes.4o Ll has been determined to encode the major capsid
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protein and L2 the minor capsid protein.4o Figure 1 depicts the organization of the
HPV 16 genome, including the location of the early and late genes.
The E6 and E7 proteins of HPV are mown to interact with specific tumor
suppressor proteins. I, 20 The E6 and E7 proteins are 150 and 100 amino acids
respectively, contain cysteine rich zinc binding regions, and have structural similarity
to one another. I, 8, 28 The E6 protein, which is inactivated in over 50% of all cancers,
has been shown to associate with the p53 protein. 8 Analysis by Crook and Vousden8
employed proteins translated in vitro in a reticulocyte lys~te to assess the complex
formation between E6 and p53. They demonstrated in high risk types that there is a
stable association between E6 oncoproteins and p53, whereas in the low risk types this
is not apparent. Those studies which included high risk HPV E6 proteins and p53
resulted in the rapid degradation ofp53. Analysis of the low risk HPV E6 exhibited no
degradation of p53 although, there was a low efficiency association detected between
HPV 6 and HPV 11 with E6 and p53. Experiments by Scheffuer et aI, in contrast, were
unable to detect any complex formation between the low risk HPV types and p53 in
vitro.9,36 The association between p53 and E6 is mediated by E6-AP, a 100 kDa
cellular protein.8 The stable formation of a triple complex leads to ubiquitination and
degradation of p53, while E6-AP and E6 protein are not reduced. I ,8 All three
components of this complex are required for degradation to proceed since it has been
~ ,
",- "'---shownLhatneitherE6--nor"E6~AP'CarffOffifa'sfab1e'associafloh Wifil'p53'aroi;e:ll--fh{;~,-
all three of these factors are crucial for the E6 mediated proteolysis ofp53.
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The E7 protein of HPV has been localized· to the nuclear matrix, and
similarities have been recognized between the HPV E7 proteins and two other DNA
tumor virus transforming proteins: SV40 large T-antigen and Adenovirus Ela.1, 36
These similarities have extended insight into the activity of the HPV E7 protein. It has
been determined that HPV E7 binds to the retinoblastoma (Rb) tumor suppressor
protein, pI07, and p 130.13' 14, 23, 48 All of these proteins are involved in regulating cell
cycle growth.14 The interaction of E7 with other mitotically active cellular proteins
also includes cyclin E, cyclin A, cyclin Dl and E2F?9, 50 Although the exact
mechanisms behind the interactions are not completely understood, it is believed that
they are significant.50
The activity of pRb in the cell cycle is required for progression through G1.14 .
pRb binds and inactivates cell proteins, including the transcription factor E2F.14 E2F
is a sequence specific DNA binding protein which regulates the expression of many
genes essential for cell division. 1 It is believed that when E7 binds to Rb the
interaction releases the transcriptionally active E2F, therefore allowing entry into DNA
synthesis.14, 38 A similarity between HPV E6 and E7 activity has been demonstrated
when comparing the high and low risk HPV types.41 The E7 proteins of the high risk
HPV types associate with Rb more efficiently than HPV E7 of the low risk types.41
• This activity'parallels E6 interaction with the tumor suppressor.protein, p53 .
• _. __ .._,.,-n.'l .. .-. ..... ~~, -;-":. -_~.__.. _-.._.. __ ._- ,~_.---._' -.",-"_.".- ." ..... -,_.-=-.~ ---._-- --~-- ----.....-,.~~-_·-=-.--:;i~~~..--.-:.-;;-:.:-:-~~:;;-~':"-::::'";.;-...:;;~~c,.~ -.,~...... ,n·::":"','1'~:!~-i·f ..t1J.~T.-r::;:.,:;::~·""r::"t~
In situ hybridization experiments45 on premali~ant lesions have suggested that
in low grade superficial intraepitheliallesions (SIL) there is controlled expression of
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E6 and E7. Therefore, there is regulated transcription of HPV E6 and E7 genes and
their expression is restricted to the superficial tenninally differentiated layers of the
epithe1ium.45 High grade lesions, in contrast, showed uncontrolled, deregulated, viral
gene expression since HPV E6 and E7 were expressed in all layers of the epithelium.6,
45 Once HPV viral genes E6 and E7 become deregulated, further molecular
modifications may occur leading to oncogenesis. II The link between HPV viral gene
expression and specific states of cellular differentiation of infected keratinocytes
suggests that HPV viral gene expression results from a complex interaction between
both viral and cellular factors.24,45
The remaining early genes of HPV include El, E2, E4 and E5. The El open
reading frame (ORF) encodes a 68-76 Kd protein and along with E2 their products are
necessary for DNA replication. I I, 40 The E4 region is contained within the E2 ORF and
although it is classified as an early gene it is actually believed to have late gene
function. E4 in HPVla has been identified as a cytoplasmic protein and is found in
abundance.4o E4 is thought to be involved in productive viral maturation. E5, similar
to E4, usually lacks an initiation codon.41 E5, though, encodes a membrane protein
with weak transforming activity.27,41
In benign HPV lesions, the HPV genome remains episomal whereas in most
host's cellular ge~ome.5, 11,45 Integration has been detennined to follow a 'specific
7
E6, E7, and the upstream regulatory region (URR) are conserved and are functionally
active, whereas other regions may be disrupted or deleted.4o,47 In most cases, during
integration HPV is disrupted in the ElfE2 region.5, 40, 45, 47 Consequently, the 5'-
sequence elements of the HPV genome are adjoined with downstream host sequences
and signaling can proceed towards transformation.5, 11, 19,40 Figure 2 illustrates the
integration pattern ofHPV into the host's genome.
HPV has been shown to have a host range limited to squamous epithelial cells.
A model,using human mammary epithelial cells as a target for HPV infection was
examined by Band et al to determine if the breast tissue may be a potential attack site·
for HPV.3 Previous work by Schiller et al demonstrated that the E6 gene of Bovine
papillomavirus type l(BPV-l) transformed C127, a mouse mammary cellline.28, 37
Band et al introduced HPV16 or HPV 18 whole genomes into normal human
mammary epithelial cells (76N).3 It was determined that the mammary cells remained
nontumorigenic even though immortalization, a reduction in growth factors, and
chromosome changes were apparent.3
Further research by Band et at2 investigated the role~ ofHPV16 'E6 and E7 in
human mammary epithelial cells. They determined that transfection of normal human
mammary epithelial cells with a s'ingle HPV gene, E6, was sufficient to immortalize
the cells and reduce their growth factor requirements.2 The disruption 'of the early
~----------
genes El, E2, E4, ~d E7 did not hinder the immortalization activity of the mv··
gen~me. It was only the disruption of E6 which eliminated immortalization. Thus,
~~~':;-::-;"";'1'-i-:;~·~;:;'"'-;:~7:..~::'~~·":";:~''''L:~_:~~'-:>' '."7...7",,;'::-;1:.-'.:--~-:;:-::::-:r.~-~'-T_h"'_..o-.tt,~,?-::>.~7'~:'T7'_r.~~~~r.-.~-~.'t~,~;:.~i':j7:">7;-;:v~,:~o:"'l~.~.:-;:i<~_~~~:'!;:,.-, ... :.::r=:.:..7:,7.~~...-:zY_~:-~-l::·.~.:~_~;:7:;.~~,O:;~'-·;-~'7,~;,;:.~-,::<~,~~~":':o~;r-::;:;;-::-~:<:"S"",\,,~
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HPV E6 is sufficient for immortalization in human mammary epithelial cells.2 In
addition, Band et al demonstrated that HPV16 E6 immortalized cells had the same
reduced growth factor requirements as found in whole genome transfected cells.2 This
information has established a basis for the independent transforming activities
possessed by the HPV E6 gene.
These preliminary findings by Band and Schi111ing prompted questions
concerning the relationship between HPV and the development of mammary tumors.
Since HPV E6 and E7 proteins are mown to form complexes with p53 and Rb,
transfectants were also examined for the presence or absence ofp53 and Rb proteins.2
Analysis showed that transfectants with E6 and E61E7 had normal functional Rb
protein.2 The E6 and E61E7 immortalized cells had a drastic reduction in p53 protein
when compared with 76N parent cells.2 Western blots were performed to determine
the levels of p53 more quantitatively. The protein analysis demonstrated undetectable
levels of p53 protein.2 These findings are significant since research has shown that
mammary epithelium is extremely sensitive to alterations ofp53 regulation.41 This is
consistent with a high occurrence ofp53 mutations in breast cancer.41
Research by Halbert et aIlS assessed the contribution of HPV E6 and E7 to
immortalization not in m~ary tissue but instead, human foreskin epithelial cells.
The E6.and E7 genes of HPV6b and HPV16 were introduced separately and in
---- ----combination-into--humaILioreskin__~a~ithelial cells._Analysis demonstrated that the
l't ------ ---- -
WV16 E7 gene could immortalize primary human keratinocytes without the viral E6 .
• 1 'C l .
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gene. E6 activity was shown, though, to significantly enhance the efficiency of the E7
immortalizing activity. The colonies which contained HPV16 E6/E7 exhibited less
cell crisis and some did not undergo crisis at all. This increased immortalization may
be due to additional signaling by HPV16 E6 for the cells to proliferate. The data of
Halbert et al determined that infection ofcells with retroviruses carrying the HPV16 E6
ORF alone did not result in immortalization, whereas Band concluded that HPV E6
was sufficient for immortalization of normal human mammary epithelial cells.2, 19
Since the effects of HPV E6 on foreskin epithelium is different versus mammary
tissue, it may be suggested that the activity of HPV oncoproteins may vary depending
on the tissue type and location.
The divergent results of HPV activity encountered in various tissue types
clearly established that there may be differences in HPV transforming capabilities
,
found in mammary epithelium versus other epithelial cell types. HPV and human
mammary epithelium research determined that HPV E6 alone is sufficient· for
immortalization.2 The presence of HPV E7 is not required.2 Research suggests that
mammary epithelium may not require interaction with Rb, or an altered Rb activity
may already be present, thus allowing cells to undergo immortalization without the
presence ofE7.41
~revious analysis has produced conflicting data with regard to any role of HPV
III
. ., .._..__._ '.'._ ----.in-breast-cancer.. --Research::-by"Ikenberg""examinedcchuman::"papilloma:v:irus,..DNA.;'in"~·";2-'u~ . .-
"
distant metastases of cervical cancer.21 Through Southern hybridization techniques
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they identified HPV 16 DNA in a breast cancer metastasis?1 A study by Di Lonardo et
al. examined histological sections from paraffin-embedded breast carcinomas and
auxilIary lymph nodes for the presence of HPV.12 Polymerase Chain Reaction analysis
revealed 5 specimens out of 17 (29%) to contain HPV 16 DNA.12 Although the
researchers maintained only a small sample size, their data implicates HPV to be
present in some breast tissue. 12 In contrast, other studies have not been able to identify
HPV in breast carcinomas. Bratthauer et al. examined 43 specimens by PCR and
Southern blotting and found none to be positive for HPV types 6, 11, 16, and 18.7
Analysis by Wrede et al. evaluated 80 breast tumors and found all to be negative for
HPV.49 Although they had a larger sample size, they utilized primers directed against
sequences for the E7 ORF of HPV and specific only for types 16 and 18.49 A more
recent study by Gopalkrishna et al examined 26 fine needle aspirate specimens from
breast cancer patients and four breast tumor biopsies. 15 Similar to research by Wrede,
the tissues were analyzed by both PCR and Southern hybridization for the presence of
HPV16 and HPV18 DNA.15 All specimens were determined to be negative for HPV
DNA.15
The results obtained from studies thus far have determined the role of HPV in
mammary epithelial cells to be unclear. The evidence presented requires further
analysis of mammary tissue for the presence of the human papilIomavirus, in
particular, the E6' 'gene of HPV. For my masters thesis I examined 129 breast
carcinoma specimens for the presence of the HPV E6 gene, the region which has been
, -
,·· ... ",,·.•.v,"- ",_,_"w.~ ~_.,.>:' ~" .... ,,,.",, " __"._,,,.~ •.••.••,.~._.v -"'·'~"~~'~"'···i~" ,.'.'_ .....':.:. r~.~l';:..;. ..; .. ,--...~,~::.~......... _ ._..--_~ .." - •. _'.-W-" - .-
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found to independently immortalize human breast epithelial cells. The use of 129
specimens in my research allowed for a more thorough examination in determining the
presence or absence of HPV genetic material in mammary tissue. The Polymerase
Chain Reaction (PCR) was utilized to examine the mammary tissue lysates. The
primers designed for the assay were ones which would detect a broad range of HPV
types, including those that have oncogenic potential. Southern hybridization to probes
within the HPV E6 amplified region was performed to confirm putative HPV positive,
specimens. In conjunction with the E6 region, I also amplified a 110 base pair region of
the cellular ~-globin gene to serve as an internal control. The data collected from my
analysis should allow further insight into the possible role of HPV in breast cancer.
Furthermore, my data will be coordinated with other research done in Dr. Sands' lab;
specifically, the combination of experimental results involving E6 and Ll regions of
HPV will provide distinct but comparable databases of the prevalence ofHPV in breast
/'
carcmomas.
•
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MATE~SANDMETHODS
Breast Carcinoma Specimens
Paraffin-embedded breast cancer specimens were provided by Dr. Antonio Amortegui,
M.D. from the University ofPittsburgh's Magee Women's Hospital. The breast biopsy
specimens were prepared from fresh samples obtained between 1993 and 1994. Each
tissue sample received had documented dates of each biopsy in the event further
patient history was needed.
Control DNA
In addition to the 129 breast carcinoma specimens that were analyzed, each series of
experiments included both positive and negative controls (cells with or without
integrated HPV DNA) and also a negative control which lacked any introduction of
DNA. 16 The HPV positive controls were a SiHa cervical cell line (HPV 16,
approximately 1-2 copies/cell) and a Hela cervical cell line (HPV 18, approximately 50
copies/cell ).39 A C33 cervical carcinoma cell line served as an HPV negative control.
These various control cell lines allowed for the detection of introduced contamination
within each PCR reaction setup.16 The cell lines were obtained from The American
Type Culture .Collection (ATCC, Rockville, MD) and grown in Eagles Minimum
..... c:= . '=='-··-Essential·Medium-(Sigma,-St...Louis"Mo.)._-This.medium,..(PHL7.2.5lcPlltai~d. .911~ __ _._
vial 9.6 g Sigma M0643, 2.6g HEPES," 2.2g NaHC03, lOml of penicillin /
streptomycin (10mg / ml) and 10% bovine calf serum diluted in 1 L of ddH20. For
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PCR, trypsi~zed cells were stored in phosphate-buffered saline (PBS) at _200 C. The
tubes were thawed as needed, boiled for 10 minutes and centrifuged at 795 g for five
minutes. The supernatant was then used for the PCR reaction.
Amplification of HPV E6 DNA in Mammary Tissue by Polymerase Chain
Reaction
Polymerase Chain Reaction is an in vitro technique used to amplify specific DNA
sequences.33 The experimental protocol required four HPV E6 primers which
amplified a broad range of HPV types. They were synthesized by DNA International,
with the following sequence:
HPV E6 PRIMERS
--Consensus Primers
WD 76 sequence
5'-CGGTTSAACCGAAAMCGG-3'
WD 67 sequence
5'-WGCAWATGGAWWGCYGTCTC-3'
..
-~---- -'':'-='::.~ ~-~-- --- - - - -
18 mer
20 mer
-----.__._----_._~- -~~---. - -------- -.__...- .... _- ..
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HPV 18 Primers
WD 72 sequence
5'-CGGTCGGGACCGAAAACGG-3'
WD 66 sequence
5'-AGCATGCGGTATACTGTCTC-3'
19mer
20mer
W=A+T S=G+C R=A+G Y=C+T M=A+C
WD 72 and WD 66 were included in the peR reaction to ensure the amplification of
HPV 18 if present in the tissue samples. In addition, WD 76 and WD 67 contain two
and five degenerate positions.35 This allowed for amplification of a range of HPV
types which included 6, 11, 16,31,33, and 35. The consensus primers are designed to
amplify a 250bp region within the HPV E6 gene. WD 72/ 76 are positive strand
primers and are located upstream of the open reading frame of the E6 gene, while
WD66/67 are negative strand primers.35 The negative strand primers are located in the
E6 coding region.35 A representative chart ofHPV E6 pIjrners is shown in Table 1.
Amplification of the E6 gene allowed for detection of a region that is mown to
be uniformly expressed in HPV-induced tumors even though the HPV genome is often
disrupted and rearranged due to integration. 14 The primers used in my analysis were
consensus primers which were c.omplementary to a conserved region of the E6 gene
" .
and could detect HPVs from three subgroupS.35. They amplified HPV types 6, 11, 16,
18, 31, 33, and 35, which are the HPV types most commonly associated with genital
lesions. Along with the HPV E6 research, another analysis was concurrently
15
perfonned in our laboratory on these same samples using a different region of the HPV
genome (the Ll gene ofHPV, a highly conserved region among all papillomaviruses).
This study also required the use of consensus primers to detect the same HPV types.
Therefore, the use of these two sets of consensus primers (for E6 and Ll regions of
HPV DNA) established a reliable strategy to thoroughly determine the presence or
absence ofHPV in mammary tissue.
Amplification of the p-globin gene by the Polymerase Chain Reaction
In addition to the HPV E6 primers, another set ofprimers was used to amplify a
region of the human P-globin gene. The primers were designated PC03IPC04 and
they amplified a 110 bp region.17 PC03 and PC04 served as an internal control to
assess DNA integrity and the relative quantity of DNA in the samples. This internal
control also monitored for the presence of inhibitors, thus allowing negative results to
be accurately interpreted. Other P-globin primers used in our lab amplified a 260bp
region, and they were used in conjunction with primers for the L1 region, which
amplified a 450bp region. In my analysis a P-globin PCR product of 260bp would
have been too similar in molecular weight to the 250 bp amplimer produced by the E6
primers. Therefore, I chose PC03IPC04 for my PCR protocol.
1t\
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PCR Primers for ~-2Iobin Gene Amplification
PC03 sequence
5'- ACACAACTGTGTTCACTAGC - 3'
PC04 sequence
5'- CAACTTCATCCACGTTCACC - 3'
• The E6 and P-globin amplification reaction contained 5 pmol each of the P-
globin primers (pC03 and PC04)4, 10 pmol of WD72, 1Opmol WD66, 40 pmol of
WD76 and 40 pmol ofWD67. The E6 and P-globin primers were added to a mixture
that included lOmM Tris-HCI (pHS.S), 50mM potassium chloride, 4mM MgCI2, and
200llM concentration ofeach deoxyribonucleotide triphosphate. Each reaction had 1~l
of a breast carcinoma lysate, HPV positive control, HPV negative control or a DNA
blank control (ddH20) added to the 500~L microcentrifuge tube along with an
Ampliwax pellet (perkin Elmer Cetus). The reaction mixture was hot started at 9So C
for ten minutes in a DNA Thermal Cycler (perkin Elmer Cetus Instruments, USA). 2.5
U of Taq DNA polymerase (promega Corp., Madison, WI) was introduced into the
reaction tube and subjected to 40 amplification cycles at established parameters. The
cycling temperatures and times are indicated below:
Denature template at 94° C for 1 minute
Anne~l primers at 55°C for 1 minute It
Extension at 72°C for 2 minutes
17
Electrophoresis of HPV and ~-globin peR Products
The PCR products were electrophoresed at lOOV for two hours in IX Tris- ""
borate/EDTA electrophoresis buffer (TBE pH 8.0) through standard 10%
polyacrylamide gels. Polyacrylamide allowed better resolution and band separation of
the low molecular weight PCR products than electrophoresis using agarose. The gels
were stained in ethidium bromide for fifteen minutes, and transillumination by UV
light was used to visualize the bands. The molecular weight marker, <1lX174 DNA cut
with HinfI (promega Corp, Madison, WI), contained fragment lengths 24 bp to 726 bp
and was utilized to size the bands obtained through electrophoresis.
Those breast specimens which had amplification products considered to be
putative positives for HPV were subsequently processed for Southern blotting. This
was determined from the band migration pattern on the gels. If a visible band was
present in the vicinity of 250 bp, the sample was considered to possibly contain HPV
DNA. The experimental design used for these specimens included electrophoresis
through an agarose gel at 100V for 1.5 hours in IX Tris-acetate / EDTA
electrophoresis buffer (TAE pH 8.0). It was determined that agarose gels- were easier
than thin polyacrylamide gels to manipulate when preparing the Southern blots.
Probes for Southern Hybridization
The probes used for South~rn hybridizat~on contained complementary base
sequences to the E6 amplified region. They allowed for hybridization to HPV types
-most frequently found in genitallesions;- and-also·-included--those·· which, have been
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implicated in the etiology ofneoplasia. The probes hybridized to E6 sequences ofHPV
types 6, 11, 16, 18,31, 33, and 35. The first was a consensus probe designated E6C.
Since a consensus probe could not be found that included HPV 18, the second probe
(E618) was type-specific for HPY 18. The probes were designed using BLAST
(http://www.ncbi.n1m.nih.gov:80/cgi-bin/BLAST/nph-blast), which is a computer
program that can search for homologies in databases. Short stretches of HPVE6 DNA
were compared to various HPV types to determine if there was enough
complementarity between the two to allow basepairing. In addition, the probes were
constructed to have complementary sequences to those HPV types which are most
prevalent in genital lesions. Once the nucleotide sequences were determined, they
were sent to Genosys Biotechnologies, Inc for synthesis.
HPVE6C
5'-SWGAGRTWTWWKMHTWTGC-3, 19 mer
HPVE618
5'-AATTTGCATTTAAAGATTT-3 , 19mer
W=A+T S+G+C R=A+G Y=C+T M=A+C K=G+T H=C+T+A
E6C and E618 Digoxigenin-1.1-ddUTP Labeling Procedure
The·methodused to label the probes was aii.oligonucleotide labeling reaction'
containing Boehringer Mannheim (Indianapolis, IN) digoxigenin-11-ddUTP(pig-
~dUTP), which results in the_ ~cldition of on~ digoxigenin residue per oligonucleotide
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using the enzyme terminal transferase. The 3'-end labeling procedure could detect as
little as IOpg of control DNA and, in addition, has maximum probe specificity. E6C
and E618 were labeled using the Boehringer Mannheim Genius 5 Oligonucleotide 3'-
end Labeling Kit. The probes were then analyzed to estimate their concentrations.
Serial dilutions were made of the Dig-labeled probes and a control labeled probe. The
HPVE6C and HPVE618 dilutions were spotted and UV fixed onto a nylon membrane
along with a control labeled probe. Following color detection of the membrane, the
intensity of the HPVE6C and HPVE618 dilutions were compared with the control
dilutions to estimate the yield of Dig-ddUTP labeled probe. The amount of Dig-
labeled oligonucleotide was determined to be 2.5 pmollJ-l1 for both HPVE6C and
HPVEI8. Since each probe was suspended in lOOJ-lL Tris-EDTA (TE pH 8.0), the
total yield for each was 25Opmol. The ideal concentration of probe for hybridization is
1-10 pmol per ml.. Therefore, twenty microliters of each probe was aliquoted into 5
ml ofprehybridization buffer to generate a concentration of 1Opmol / ml.
Southern Hybridization ofpeR Products
In addition to the putative HPV positive specimens, control DNA specimens
t ~
were also used in the Southern hybridization experiments. HPV positive SiHa DNA,
HPV negative C33 DNA and also a specimen with no DNA were included. A
.' .
. Boehring~rMannheim~Dig mole~ular weight marker (XI) was also run to measure the-
band sizes during color detection of the Boehringer Mannheim's positively charged
membranes.
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The wells of the agarose were loaded with 8111 of an amplified PCR product
along with 2111 Blue/Orange 6X Loading Dye(promega). Following electrophoresis,
the gel was placed in ethidium bromide for staining. Once photographed, the agarose
gel was incubated in 250mM HCI for five minutes for depurination. The gel was
quickly rinsed in sterile distilled water. The agarose was then submerged in 0.5N
NaOH, 1.5M NaCI for 15 - 30 minutes to denature the DNA target prior to transfer.
The last wash was 1.0 M Tris-HCI, pH 8.0; 1.5 M NaCI for 20 minutes to neutralize
the gel. The gel was then prepared for overnight transfer to the positively charged
nylon membrane. The DNA from the agarose was transferred by capillary action to the
nylon membrane soaked in lOX Standard Saline Citrate (SSC). Following overnight
transfer, UV crosslinking was performed to fix DNA to the membrane.
Prehybridization of the nylon membrane for one to two hours at 50° C prepared
the membrane for probe hybridization by blocking non-specific hybridization of
nucleic acids on the membrane. Standard prehybridization solution was prepared using
5X SSC, 1.0% (w/v) Blocking reagent for nucleic acid hybridization, 0.1% N-
lauroy1sarcosine, and 0.02% sodium dodecyl sulfate (SDS). The membrane was then
placed in standard hybridization solution (Dig-labeled probe diluted in standard
prehybridization solution) overnight at 50° C.
Follo\¥ing this overnight incubation to allow hybridization with the E6C an~
.:;.:.: ',':_:, !'...." ...'-. " _.' " .... :; <'J""; • r·I-"~':'·-L--:;'"'~·"-···· '-'.-,," - "".-,'-"'" ... ·n;~"-';. n-'" ."., ·'·"-':-.,~n-J:'(17_1.:L..-.r.-':UI:-~'.:.~1~,\~..... .,.,;,-.."., .. ".- ,-- "':'~ .,"'··'.,.:·... F~'·-~'·-,:.·· ...· T=~."J-,.,.·-,·.~·f..,.,.;· ..rr1·:~-' .... --,'?_"t.;i
,:",' ~;~"':.':"~":i!;jT~.?--;:'Io(-",,·Ti.;":~·~:"'I."""~;'':'''''·'':''':;;':;~~:';'--· ~ • "" _
E618 probe, the membrane was washed to remove unbound probe. The membrane was
'\ ""-
rinsed twice in 2X SSC/ 0.1% Sodium Dodecyl Sulfate (SDS) for five minutes at
room temperature, once for five minutes in 0.5X SSC containing 0.1%SDS, and then
21
twice for five minutes at the hybridization temperature (500 C) in 0.5X SSC / 0.1 %
SDS.
Color Detection of the Hybridized Membrane
The colorimetric detection of the nylon membrane was performed with ~T
solution and X-phosphate solution. The membrane was first equilibrated in Boehringer
Mannheim Genius 1 buffer (100mM Tris-HCL, 150 mM NaCI; pH 7.5). Incubation in
Boehringer Mannheim Genius 2 (2% [w/v] Blocking reagent for nucleic acid
hybridization dissolved in Genius buffer 1) was then necessary for sufficient blocking
of the membrane. Following blocking, the nylon membrane was incubated for 30
minutes in anti-Dig alkaline phosphatase working antibody solution. The working
solution was prepared by diluting Boehringer Mannheim anti-Dig alkaline phosphatase
1:5,000 in Genius 2 for a working concentration of 150mU/ml. After incubation, the
membrane was transferred to a fresh tray and washed twice, five minutes per wash in
Genius buffer 1 to remove unbound antibody. The membrane was then equilibrated in
Boehringer Mannheim Genius buffer 3 (100mM Tris-HCI, 100mM NaCl, 50mM
MgCI2; pH 9.5) for 2 minutes and submerged in the Boehringer Mannheim color
substrate solution (45 ~l NBT solution [cat. no. 1383 213] and 35 ~l X-phosphate
solution [cat. no. 1383 221] in 10 ml of Genius buffer 3) overnight for color
"'n_, ...\...;~~~, ..... .:ao-:-_-.~ ".':.:..>';....r.:._~ .• \,;J::"-·'J-·-·;.·.!·..",.;_,.;·\~\.·.-t:.z:,,?:\:"-::.~~ _ --" .. ~ ·a~;,~"•.. _ '. • _, -,;,- :n', "0'.":,"'.' .. ~'. -". :.•."."" ...... >,-";0.,, ,......1:' ":tt.:,.-.;...-:;-:, ... ,•.}, •. ': ..... ~.-...:.?"' = ,-.-, "-~"n-.,' .. ~. _ . ., '''' ~~ ••.• .-.--'~• .'T)
development in the dark. Once the desired bands were detected the membrane was
rinsed in sterile water to stop the reaction. The membrane was then kept from light and
dried at room temperature
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RESULTS
I. PCRASSAY
The results reported in this thesis involve the analysis of 129 breast carcinoma
lysates via the Polymerase Chain Reaction for the presence of HPV E6 region DNA.
Concurrent research has been performed on these specimens in our laboratory, with
concentration on the HPV Ll region. Ll is the most highliconserved region ofHPV
and during integration, Ll and L2 are retained along with the 5'-early ORF which
contains functionally active HPV E6 and E7. Therefore, the combined analysis ofboth
HPV E6 and Ll allowed for detection of the components consistently expressed when
HPV integrates into the host genome.
The initial phase of my research determined whether or not the breast
carcinoma specimens contained amplifiable DNA. ~-globin primers, PC03IPC04,
were used in the PCR assay to determine the DNA integrity of the samples. These
primers amplified a 110bp region of the cellular ~-globin gene which has been
determined to be present in all human DNA. Those samples which had a visible band
at 110 bp were included in the analysis, since they contained viable DNA. The PCR
mixtures also included two sets of HPV E6 primers, which amplifies a 250 bp region
of the HPV genome. If a breast sample exhibited a band migrating in this region the
samplewas considered to be- a putative HPV positive sample and was saved for furthe~
-_ _;:::.:...;-'.:::::.:..:.....:... •..;..:.:....;.~--:..;;::':.:_;::~..•:; ~·_'_';,,·::-',;~·;~~.~;;:::..7r-':~~~·~'·~_}-~-:~'~:t:':l~~I~::l:n'~_~'~>;j:-""::~;"-'""':-";';;:3{!'f;""~~"" ,.. "_ .. -: ".. _." ~ .. _
analysis.
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The products obtained from PCR were electrophoresed using a standard 10%
polyacrylamide gel, allowing for optimal resolution. Specifically, polyacrylamide gels
made the ~-globin bands easier to visualize on the gels comp'ared to agarose gels. The
molecular weight marker, ~XI74/HinfI, was used since its migration pattern had
numerous bands in the range of 100 to 350 bp.
PCR amplification determined 127 of the 129 mammary carcinomas to have
detectable ~-globin DNA. The presence of a ~-globin amplified product ensured that
specimens which lacked DNA or had degraded DNA were not included in the analysis.
This alleviated the prospect of false negative being incorporated in the study. Breast
carcinoma specimens 6 and 50 were excluded from the data since they were repeatedly
amplified via PCR and each time revealed the absence ofDNA.
All PCR sets contained the clinical breast specimens in addition to a series of
controls, which included a water blank (which was absent of any DNA), an HPV
negative control (C33 cell line) and a positive HPV control (either SiHa [HPVI6] or
Hela [HPVI8] cell line). The proper technique for the experimental procedure also
required the use of filter pipette tips, therefore decreasing the risk of carryover
contamination. Figure 3 depicts an example of positive and negative controls included
in each PCR set. SiHa, the HPV16 cell line, revealed a ~-globin band at 110 bp and,
in addition, the presence of an HPV E6 band at 250 bp in lane 2. Lane no. 4 contained
- ,
C33, the HPV negative cell control, and as expected only a ~-globin amplified product
. ......
was visible. The DNA blank, which confirms that no DNA had been introduced, is
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absent of any bands. The remaining lanes contained breast samples 103 through 108.
All of these specimens had a visible p-globin band except samples 104 and 106. PCR
was later repeated on these and a P-globin amplified band was visible. In this PCR
series all samples which had P-globin bands were negative for HPV, excluding the
positive control.
II. Southern Analysis
Polyacrylamide gels were examined under ultraviolet light for the presence of a
visible HPV E6 band. In order to confirm if the PCR amplified product contained
HPV DNA the gels were further prepared for Southern analysis. The protocol required
overnight hybridization using the probes HPVE6C and HPVE6l8. This technique
allowed for detection ofHPV types 6, 11, 16, 18,31,33, and 35. In addition, it may
. have allowed detection of a novel or yet uncharacterized HPV type.
Southern analysis was performed on those specimens which had a visible band
that migrated near 250 bp, and also Sahlples which had previously been determined to
contain HPV Ll DNA. These parameters allowed a thorough examination of all
potential HPV positive samples. The data could then be compared to concurrent
studies in our laboratory to determine if any similarities were present between the
specimens and HPV genome regions. Also included in the Southern transfer
experiments were some sPRcimens which initially lacked p-globin amplification. PCR
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was repeated. on these samples and they were electrophoresed along with others that
were considered to be putative HPV positive specimens.
In order to verify that my HPV E6 probes would hybridize to the HPV types
most prevalent in genital lesions I performed PCR on plasmids containing full-length
HPV. HPV 6, 11, 16, and 18 were provided by Dr. Harold zur Hausen, German Cancer
Research Center in Heidelberg, Germany. HPV 33 was provided by Dr. Gerard Orth,
Pasteur Institute, Paris, France and HPV 31and 35 were obtained from ATCC
(American Type Culture Collection, Rockville, Maryland). All types, except for HPV
6, contained full length viral genomes cloned into plasmid pBR322. HPV 6 was
instead cloned into the pUC 19 vector. Each of the vectors were then transfected into
E. coli JMI09 and the ampicillin resistant colonies were used for plasmid preparation.
The samples were electrophoresed for 90 minutes at 100V in a 2% agarose gel. The
representative gel is shown in Figure 4. .Lane 1 exhibits the migration pattern of
~XI74IHinfI. Lane 2 contains the Dig molecular weight marker. This lane shows no
visible bands since they are not apparent until after color detection of the membrane.
Lanes 3 and 4 were controls, C33 and a DNA water blank. The presence of a band in
the negative control lane is due to the dimerization of the primers introduced in the
reaction mixtures. This is not the result of contamination. Lanes 5 through 11 contain
the HPV ~es which_shoul~ hY~!i~!~~!o_t!J.e ~y...~.~_p.!ob~.~.,ll~~(tm}h~,.,-W1,'lIYrs,~""'E""''''~ls- ..r-" ....
. ~- ,----:,~.-.•.-.,..,.:";.::;:.,..5:-,:::-:.-....,-,-;,."";7'7-:-:.\--:c-" •.- _.•,;~ - : _ .::0. _.,-. ••. _ ..••..••_ .._ .. ..• ,,-.- .• -_~", , .• ,' .', ..,·k •• ·.. .• ~_, : ,#J.
Electrophoresis results showed a visible ~-globin 110 bp band and also an HPV E6 250
bp band in lanes 5 - 11. The .last five lanes contained samples 120, 19, 55, 87 and 99.
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In specimens 120, 19 and 55 a faint ~-globin band can be observed while samples 87
and 99 are absent of any bands. The DNA from the agarose gel was then transferred
overnight to a nitrocellulose membrane. The gel was subsequently hybridized with
buffer containing HPV E6C and E618 probes. The membrane results are shown in
Figure 5. Although the Dig molecular weight marker is faint on the membrane, the
bands could be distinguished. The visible bands in lanes five through eleven
confirmed hybridization ofHPV E6 probes to HPV types 6, 11, 16, 18,31,33, and 35.
Therefore, the HPV E6 probes were functioning correctly in the Southern analysis.
The membrane also did exhibit the presence of some nonspecific hybridization. This·
, did not interfere though with the interpretation ofmy results.
Another experiment performed was PCR of an HPV positive control in
dilution. This was done to roughly establish the sensitivity of the hybridization assay
used in our laboratory. Dilutions were made 10-\ 10-2, 10-3, 10-4, and 10-5 of SiHa
control lysates. PCR was then performed followed by electrophoresis of the PCR
products. The SiHa undiluted concentration was determined to be 3.2 x 105 cells/ml.
The concentrations of the serial dilutions would then be approximately 3.2 x 104
cells/ml, 3.2 x 103 cells/ml, 3.2 x 102 cells/ml, 32 cells/ml and 3.2 cells/ml. The SiHa
stock cells were diluted with proteinase solution and frozen at _200 C for storage.
Figure 6' is representative ofthe agarose gel which was 'electrophoresed£or 2.5 hours·.at -
60V. As expected, the agarose showed gradual diminishing HPV E6 bands in the
dilution series. Undiluted Hela and SiHa controls in lanes 3 and 6 show an extremely
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bright HPV E6 band on the agarose. Lanes 7 through 11 contain the dilution series and
one can see the presence of a visible HPV E6 band at 250 bp in all samples whereas the
P-globin amplimer at 110 bp becomes nearly invisible after the SiHa 10-3 dilution.
Breast samples 30, 35, 59, 42 and 79 were also included on the agarose in lanes 12
through 16. These samples all contained a visible p-globin amplimer.
Southern analysis results of the processed membrane are depicted in Figure 7.
A visible HPV E6 DNA band was present in lanes containing Hela(undiluted) and
SiHa undiluted, SiHa 10-1, SiHa 10-2, SiHa 10-3 and SiHa lO-4(lanes 3, 6 - 10). The
sample diluted 10-5 apparently had insufficient amounts of HPV DNA to be detected.
This showed that although a band was visible in the stained gel in the 250 bp region,
HPV was not detected in the Southern. Therefore, this band present on the agarose
was most likely the result of amplified genomic DNA. The results obtained from this
serial dilution experiment established that a specimen must contain approximately 32
cells / ml which contain one to two copies of HPV per cell in order to be detected by
Southern analysis. In addition to the Hela undiluted and SiHa dilution series it was
observed that breast carcinoma specimen no. 59 had a detectable HPV E6 band on the
1
membrane.
The specimens in which I obtained an HPV E6 band included samples 3, 26,
31, 42, 59, 79, -80, 81, 87, 99, 116, and 123.Jlybridization of the nitrocellulose ~
;.; .". - .
membrane with1IPV E6C and E618 probes followed by colorimetric detection showed
. .
a visible HPV-E6 band-at 250 bp for all of these samples. The data collected from thiSo__-
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analysis concerning the HPV E6 region was then compared to other results found on
these specimens. HPV E6 analysis determined 12 of 127 specimens, approximately
9%, to be HPV E6 positive. The concurrent HPV Ll study in our laboratory has
documented 14 HPV Ll positives, although not all samples have been evaluated to
date. Table 2 depicts the data obtained from all studies in our laboratory on the
presence ofHPV DNA in mammary carcinoma specimens.
Breast samples that showed a visible HPV E6 band were confirmed by repeat
analysis. The data I collected established samples 87 and 99 to be HPV positive.
Earlier studies suggested that these two specimens might be HPV positive. Figure 8
depicts the membrane results of mammary samples 19, 55, 87, 99, and 116. The
electrophoresis results did not show the presence of a ~-globin band in specimen 19.
This specimen was later repeated until ~-globin DNA was detected and further analysis
established it to be HPV negative. Sample 55 was considered to be HPV negative,
while mammary specimens 87, 99 and 116 were designated as HPVE6 positive.
The HPV E6 data were next compared to results obtained from analysis of the
mammary specimens for the HPV Ll region. HPV E6 DNA was determined to be
present in 7 of the same samples from the concurrent study (26,42, 79, 80, 81, 87 and
116) and, in addition, matched two samples from an earlier analyis (87 and 99) in our
laboratory. Although 6% ofthe mapnnary.carcinomas were positive for both HPV E6
. "
and Ll, the possibility ofcbn~aminationintroduced into ,the contiguous samples 79, 80,
and 81 must be addressed. A technique such as in situ hybridization would determine
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if contamination was a factor involved in the results obtained from these three
specimens. In the case of contaminated specimens the HPV DNA would be present
outside of the intact cells rather than inside. The remaining HPV E6 positive
specimens from my analysis and the Ll studies did not correlate. Those specimens
which were positive for one region and not the other may have had DNA that was
degraded and thus the other HPV region could not be detected.
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DISCUSSION
The focus of this analysis was to determine the prevalence of HPV DNA in
mammary carcinoma specimens. Of the 129 mammary tissues examined HPV E6
DNA was detected to be present in approximately 9%. The results obtained from this
study have been compared with other data from our laboratory on these breast
carcinoma specimens. This research has allowed our lab to generate a database which
to our knowledge exceeds any previously pu~lished analysis done concerning HPV and
breast epithelial tissue. The largest sample population examined previously was 80
breast carcinomas and used primers to amplify solely HPV E7 types 16 and 18.49 This
research follows findings which established that the HPV transforming gene, E7,
cannot immortalize mammary tissue.2 My research concentrated on the HPV E6
oncogene, which has been found to immortalize human mammary epithelial cells.2 In
addition, the concurrent study in our laboratory examined all samples for a 450 bp
HPV Ll amplimer. The study by Wrede et al. analyzed all of their 80 specimens for
HPV 16 and 18 E7 but only 20 samples were further examined for HPV L1.49
Southern hybridization to HPV probes was another technique used to confirm if
a mammary carcinoma actually contained HPV E6 DNA. This molecular tool
eliminated specimens that had genomic DNA amplified in the 250 bp region rather
than HPV E6 DNA. Other studies have included this technique-although in those cases
$ .. • • Q
they lacked the large sample population size.7, 12, 15 Overall, our analyses offered both
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an adequate patient population size and a thorough experimental design to more
completely examine all specimens.
All of the HPV positive specimens, including those which were positive for
both E6 and LI, should be further examined by in situ hybridization.44 This molecular
technique allows hybridization to occur within intact cells.33, 44 Analysis by this
method would confirm whether or not the HPV DNA was actually present within the
epithelial cells or if contamination had been introduced into the mammary lysates.33, 44
It can be concluded that approximately 9% of human breast carcinoma tissue
contains detectable levels of at least part of the HPV genome. Although this
percentage is low, I believe the consequences of breast cancer and its frequency in
women merit its significance. Future research concerning HPV and breast cancer
should include investigating the histories of the patients involved who had detectable
amounts of HPV E6 and LI DNA. ill particular, did the patients have a record of
abnormal pap smear cytology, multiple sexual partners or any known sexually
transmitted diseases. These data could aid in determining if HPV may have been a
causative agent in any past cervical changes. It should also be known if this episode of
breast cancer is a primary cancer or if there have been previous tumors.
The mammary specimens should also be typed to establish if one HPV type IS
more prevalent in-breasttissue-than·others. Sequence analysis ofthe"samples may also 'l ······,""·'·""1
i I
lead to discovery of a novel HPV type specific to breast epithelium. A novel HPV type
may enter the mammary epithelium through a microwound on the breast. More likely,
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perhaps, is that the presence of HPV in breast tissue is due to a metastasis from a
primary carcinoma. Typings of the mammary specimens may be able to correlate a
genital HPV infection or carcinoma with the breast carcinoma. A patient who does in
fact have a history of cervical cancer or abnormal pap smears due to HPV may exhibit
the same HPV type in both breast and cervical specimens. The next step would then be
to investigate the mechanism by which HPV migrates to the breast epithelium.
Analysis has documented cases in which genital HPV's are found at distant sites in
malignancies such as the upper aerodigestive tract,IS, 43, 49 The results from our
analysis provide data to include another location, mammary epithelial cells. As
previously mentioned, the pathway ofhow HPV enters the breast tissue is unclear. It is
also not yet understood why HPV chooses mammary tissue as its host since HPV is
usually found in genital or oral skin and mucosal surfaces.2 The presence of HPV in
mammary tissue may expose the virus to host factors not present in other epithelial
types. It has been suggested that the breast epithelium may actually provide specific
cellular interactions to HPV which allow it to induce immortalization.2 This may be a
reason why HPV E6 can immortalize breast tissue whereas human keratinocytes
require both HPV E7 and E6 to demonstrate effective immortalization?' 18, 32
Furthermore, HPV E7 has been determined to be unable to immortalize mammary
__ '''''''-C';''-' .• ,- ~-.~,epit~~liU1ll~2.Th.erefore,these cell~specific' factors present in breast tissue may be the
• - "'--'~' _ •• -- •• .i ••.••• • ..: ~:~~;'";:':-'-;"'!l:,' .. r~r..~;.... :;- .. i::..~'~'-,-.,_,.;_-~.-_",,,,- •.• _•• _. --:.;... ,-- ..... -.. -.,- .• '" ...• -_·~~;~'_~.:::-'X_l-:'~:y~':;.l!.TJJlT:::-:,j;~__ . :;.:: ',~ ';"''''\1 ;')~!"""
key to understanding how HPV may participate in the development of mammary
. . 'S
carcmomas.
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This analysis has established that HPV DNA was detected in approximately 9%
of breast carcinomas and provides a solid foundation for further exploration of these
medically important questions, concerning the role of the HPV virus in the etiology of
human breast cancer.
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WD76 URR 5'- 43-60 250
CGGTISAACC
GAAAMCGG-3'
WD67 E6 CODlNG 5'- 267-286 250
REGION WGCAWATGG
AWWGCYGTC
TC-3'
...... . ';
--...._-_._.
TABLE 1. Oligonucleotide HPV 1;6 Primer Sequences and Locations
in the HPV 16 Genome
--t""
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Table 2. Detection ofHPV in Mammary Carcinoma Specimens
Specimen no. B-globin DNA HPV E6 DNA HPVLlDNA
. 1. pos neg POS
2. pos neg neg
3. pos POS neg
4. pos neg neg
5. pos neg neg
6. NEG N/A incomplete data
7. pos neg incomplete data
8. pos neg incomplete data
9. pos neg incomplete data
10. pos neg incomplete data
11. pos neg neg
12. pos neg neg
13. pos neg neg
14. pos neg neg
15. pos neg POO
16. pos neg neg
17. pos neg POS
18. pos neg neg
19. pos neg incomplete data
-
20. pos neg neg
21. pos neg neg
22. pos neg neg
23. '- pos neg neg
... ._"~ .•. "
.'
...... _..._--
.......•
24. pos neg neg
25. pos neg neg
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Table 2. Detection ofHPV in Mammary Carcinoma Specimens
Specimen no. B-globin DNA HPVE6DNA LlHPVDNA
26. pas POS POS
27. pos neg neg
28. pas neg neg
29. pas neg neg
30. pos neg incomplete data
31. pos POS neg
32. pos neg incomplete data
33. pos neg neg
34. pos neg neg
35. pos neg neg
36. pas neg neg
37. pas neg neg
38. pas neg .incomplete data
39. pas neg incomplete data
40. pos neg POS
41. pos neg neg
42. pos POS POS
43. pas neg incomplete data
44. pos neg neg
45. pos neg incomplete data
46. pos neg incomplete data
47. pos . neg incomplete data
. _.,,~;.. 4.8. .', J)os .-
........."J;l.e~,,""'.;:,-. . incomplete data
.
.
49. pas neg incomplete data
50. NEG N/A. • incomplete data
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Table 2. Detection ofHPV in Mammary Carcinoma Specimens
Specimen no. B-globin DNA HPVE6DNA HPVLIDNA
51. pos neg incomplete data
52. pos neg incomplete data
53. pos neg incomplete data
54. pos neg incomplete data
55. pos neg incomplete data
56. pos neg incomplete data
57. pos neg incomplete data
58. pos neg incomplete data
59. pos POS incomplete data
60. pos neg incomplete data
61. pos neg incomplete data
62. ~s neg incomplete data
63. pos neg neg
64. pos neg incomplete data
65. pos neg neg
66. pos neg neg
67. }>OS neg incomplete data
68. pos neg neg
69. pos neg incomplete data
70. pos neg neg
71. pos neg neg
72. pos neg neg
73. pos neg neg
~ --
--;---7.iC .~~. - . ~ -- t> ----;----- -~ , --. - -- ~
- pos. neg neg
75. pos neg neg
-.
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Table 2. Detection ofHPV in Mammary Carcinoma Specimens
Specimen no. B-globin DNA HPVE6DNA HPVLlDNA
76. pos neg neg
77. pas neg neg
78. pos neg neg
79. pos POS POS
80. pos POS POS
81. pas POS POS
82. pos neg neg
83. pas neg neg
84. pos neg neg
85. pos neg neg
86. pas neg POS
87. pos POS POS
88. pos neg neg
89. pas neg neg
90. pas neg neg
91. pas neg neg
92. pas neg neg
93. pos neg neg
94. pas neg POS
95. pos neg neg
96. pos neg neg
97. pos neg incomplete data
98. pos neg POS
99. .
;.- - lOS
_ neg _~___"__
.
pos
---_.~-
-
~--
. , .
'.' , ..
100. pos neg neg
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Table 1. Detettion ofBPV in Mammary Careinoma Specimens
Specimen no. B-globin DNA HPVE6DNA HPVLlDNA
101. pos neg neg
102. pos neg neg
103. pos neg neg
104. pos neg incomplete data
105. pos neg ,neg
106. pos neg
-
neg
107. pos neg incomplete data
-
108. pos neg POS
109. pos neg neg
110. pos neg neg
111. pos neg neg
112. ~ neg neg
113. pos neg neg
114. pos neg neg
115. pos neg neg
116. pos POS POS
117. pos neg incomplete data
118. pos neg neg
119. pos neg neg
120. pos neg neg
121. pos neg neg
122. pos neg neg
123. pos POS neg
124. pos neg neg
.
-- - ---- . - ----- --
-- -
- _. \_. ...~-
'-'-- '-'-OS125. pos -. .. neg
4.0
Detection ofBPV in Mammary Carcinoma Specimens
Specimen no. B-globin DNA HPV E6 DNA HPVLlDNA
126. pos neg neg
127. pos neg incomplete data
128. pos neg incomplete data
129. pos neg incomplete data
LOR
Ll
Figure 1. HPV Genome Organization.
l'
Thi~.di~grcmlrel1re_sentsJhe....episomaLgen,()roe organizationofHPJl 16...Ildesignates.the.--~:;: ':.. .._--
loca~onofthe v;uious early and late ~nes in acgordance with the
'., .. nucleotide 1?asepairs of the genome.
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Figure 2 Inte~ration Pattern of the mv Genome.
The figure depicts the configuration oftbe integration pattern ofHPV. The EllE2 region
isriormally disrupted and therefore the E61E7 region becomes deregulated due to the lack
ofE2 prQtein. Therefore, the E6 and E7 viral oncoproteins are overexpressed and lead to
a neoplastic phenotype.
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427/417/413
311
245'
200
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82
9/26196 2 hr. at lOOV
Figure 3. Electrophoresis Results of Mammary Samples 103 • 108.
This 10% polacrylamide gel depicts visible (3-globin bands in all of the mammary
carcinoma specimens except 104 and 106. The controls were as expected with a 250 bp
HPV E6 band in the SiHa control lane. The C33 control only contained a cellular
(3"globin band and the DNA water blank did not have any introduced contamination.
•250
110
U/18/97 .100'V for 90 minutes
Figure 4. Electrophoresis Results of Genital HPV Types and
Mammary Specimens 120, 19, 55, 87 and 99.
The representative agarose gei clearly demonstrates that the HPV E6 primer:s used for
J.>CR analysis amPlified thoseHPV types most prevalent in g,enital infectionS. HPV E6 .
.bands arevisiblelnaIllIPVstOCk preps~'The HJ>V·bandsare~visible'along'with-othe'"=~+~"r.-;~"'·~";' ,t?'w{:u:t-1c®
cellular J3-globin 110 bp bands: . -
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Southern hybridization results ofagarose gel electrophoresed 12/18/97
Figure 5. Southern Analysis Results of Genital HPV Types and Breast
Spetimens 120, 19, 55, 87 and 99.
The results ofthe nitrocellulose membrane verifies that the HPV E6C and HPV E618
probes hybridized to the m~~ prev~entgenital ~Vtypes. It was necessary to confirm.. . . .'
---.~th~'specificitycof-thes~l'r()bes since-theywere~desi~ea~eiClusiveIYfot'tlie"~6'protocor\"jii"'\~""~,'''"''=c
.used in Dr. Sands' 'lab I . .
- ---_ .. ~- ~-
.-. ~.."'..~.~._._",..,."
-... "',,.,.....' ...-._ .... , '~',,",''''''.,"~'''-'' ....
ZSO
110
IVl7/97 60V 2.5 m.
Figure 6. Electrophoresis of lIPV SiHa in Serial Dilution and
Mammary Samples 30, 35, 59, 42, and 79.
This gel depicts1he HPV positive control in dilution. HPY E6 bands at 250-bp are
observechn these specimens along With the the 110 bp cellii1ar~~-glOljiIfampliiner. .-
After visualizing under UV light the agarose was prepared for Southern analysis.
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• :.V '; ,~r.·.~·,,1"< r' 7l1.'.'I'r! 11"';-:
"-,',:.,1.:...
11120/97 Membl'8llt Ii"om PCR 11/17/97
Figure 7. Southern Analysis Results of SiHa in Dilution and Breast
16' - Specimens 30, 35, 59, 42 and 79.
____~__ _ _ _ __ ------'.',:'.___ ~* ~ , ,'c"q·:r"Jl.:.,~,.,_
This membrane illustrates~t tlie HPVE6C andlIPVE618 probes hybridized to the
Hela lane and SiHa lysates in dilution. In addition, it was also observed that sample 59
was HPV positive. Two other Samples,42 and 79. were designated as HPV negative in
this assay although later an HPV E6 band was detected in the specimens. Therefore.
these samples-neeafurthefexaminationtocruleout'contamination,"='·~,,,,.,·',,,,,., .. , ...? .. ·.',c .. , ...
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111/98 Southern hybridization ofagarose gel electrophoresed 12129/97
Figure 8. Southern Analysis Results ofMammary Samples 19,55,87,
99 and 116.
On this membrane HPV E6 bands were visible in the lanes which contained samples 87,
99'and 116. Samples 19 and SS were repeatedly HPV negative. A band was observed in
the~C~3contrj)IIag.~j)ut since it mipd higher\thaIi the breast specimens it was
'"'."''''--_.'' ........ :r.aJ~)J,;i\'_n;:'n·-·fT ..~~~7'·~-.imf'iJlfi~,-:-·;-'"',-;-, ---:------- -- .. ----.-- ..:-----,~', ---:"'-_-. -----,------
considered to be nonspeCIfic nyc -- on.' -In addition, there Was no evidence ofan
HPV band on the agarose gel. The negative blank was absent ofany hYbridization,
therefore, contamination caryover Was not apparent
4,9
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